New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
The Latest on: Cancer Immunotherapy
via Google News
The Latest on: Cancer Immunotherapy
- London cancer researchers make number 2 their number 1 priorityon August 16, 2019 at 4:34 pm
While immunotherapy has "revolutionized" therapy for advanced ... that the flora in our guts can influence our immune system's response to diseases such as cancer. "The microbiome itself is made up of ...
- Could microorganisms in poop help treat the deadliest form of skin cancer?on August 16, 2019 at 7:34 am
Immunotherapy drugs stimulate a person's immune system to attack and destroy cancer. While they can significantly improve survival outcomes in those with melanoma, they are only effective in 40 to ...
- Buy Merck Stock Because Its Immunotherapy Drug Is a Game-Changer, Analyst Sayson August 16, 2019 at 6:17 am
Keytruda is a so-called anti-PD(L)1 inhibitor, one of a class of new immunotherapy drugs that uses the patient’s own immune system to fight cancer, and has had a major impact on cancer treatments.
- XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTICon August 15, 2019 at 10:30 pm
XYLONIX SIGNS MOU WITH BIOGEMEX TO CO-DEVELOP A PREDICTIVE CANCER IMMUNOTHERAPY TREATMENT RESPONSE DIAGNOSTIC XDX-01, a novel, point-of-care pre-treatment diagnostic, has completed early ...
- Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trialon August 15, 2019 at 10:30 am
IRVINE, Calif., Aug. 14, 2019 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing ...
- Merck's Cancer Immunotherapy Keytruda Continues to Aid Growthon August 15, 2019 at 5:30 am
The demand for checkpoint inhibitors, especially those targeting PD-1 and PD-L1, has risen significantly in the past couple of years. Cancer therapies that target either PD-1 or PD-L1 can stop ...
- Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapyon August 15, 2019 at 4:49 am
SLATE is an investigational immunotherapy directed at shared tumor-specific neoantigens (TSNA) which are derived from driver mutations, functionally important gene alterations recurrently observed in ...
- 2019 Edogawa NICHE Prize Awarded to Dr. Steven Rosenberg for His Pioneering Feat in Tackling Cancer with Immunotherapyon August 14, 2019 at 11:00 pm
The Edogawa NICHE Committee today announced that the 2019-Edogawa NICHE Prize (www.edogawanicheprize.org) has been awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective ...
- What is immunotherapy anyway? What you need to know about this exciting cancer treatmenton August 14, 2019 at 6:56 am
One of the most exciting advancements in cancer treatment in recent years is immunotherapy, which uses the body's own immune system to fight cancer. Many people became aware of immunotherapy when ...
- Better tools, better cancer immunotherapyon August 9, 2019 at 7:53 am
In the journal Science Immunology, researchers from DTU Health Technology and Jacobs University in Bremen have just published their cutting-edge research demonstrating advancement in detection of ...
via Bing News